Search

The article provides guidelines for pharmacists on proriasis and psoriatic arthritis. Topics covered include the signs and symptoms of psoriatic arthritis and the use of screening tools to identify patients, the treatment guidelines for the diseases and the efficacy and safety of treatments for both conditions. Also mentioned are the metabolic comorbidities for psoriasis such as metabolic syndrome, cardiovascular disease and diabetes.

Most nurses will encounter patients with dry skin conditions such as atopic eczema and psoriasis in their everyday practice. Emollients can be beneficial for most dry skin conditions, although they are widely underused. Increased knowledge and awareness of the benefits and optimal use of emollient therapy can improve patient care and outcomes. [ABSTRACT FROM AUTHOR]

Psoriasis is a common, chronic skin condition and nurses can expect to encounter patients with psoriasis in both primary and secondary care settings. This article focuses on the physical and psychosocial effects of the condition and on appropriate management strategies, including the use of biologic therapies to treat moderate to severe psoriasis. Quality of life issues are also addressed. [ABSTRACT FROM AUTHOR]

The article reports that pharmaceutical firm AstraZeneca has changed its partner for antibodies against skin diseases. Topics discussed include licensing of European rights to brodalumab, a monoclonal antibody for treating plaque psoriasis, to the pharmaceutical firm Leo Pharma, licensing of tralokinumab, an anti-IL-13 monoclonal antibody for treating atopic dermatitis, to Leo Pharma for dermatology uses and end of licensing to Valeant Pharmaceuticals.

The article presents the author's opinion on the use of biologics in psoriasis. Topics discussed include high cost of biologics, cost savings on biologics through the use of biosimilars, and transformation of the management of patients by biologics. Also being discussed are the new biologics for psoriasis like adalimumab.

The article focuses on psoriasis, a skin disease that causes scaling and inflammation, with patches of thick red skin generally occurring around the elbows, knees, legs, scalp, lower back, face, palms, and the soles of the feet. Topics discussed include plaque psoriasis and guttate psoriasis, symptoms of psoriasis, the percentage of people who reported psoriasis as a problem in everyday life, and treatment.

The article discusses the disease called psoriasis, which is defined as a chronic relapsing disease characterized by pruritic and erythematous lesions with well-demarcated papules and plaques. The treatment options against the disease include phototherapy or laser therapy, topical agents and biologics. The treatment guidelines issued by the American Academy of Dermatology to treat psoriasis and psoriatic arthritis in 2011 are also cited.

The article focuses on the findings of the public health researchers at Johns Hopkins University Bloomberg School that the generic biologic drugs appear equivalent to its brand name counterpart. Topics include the safety and effectiveness profiles of the biosimilar drugs, the use of infliximab biologic drug for treating rheumatoid arthritis, inflammatory bowel disease, and psoriasis, and the U.S. Food and Drug Administration (FDA) approval of Zarxio and Inflectra biosimilars.

The article evaluates several pharmaceutical products including the Sernivo (betamethasone dipropionate) for plaque psoriasis by Dr. Reddy's Laboratories Ltd., the Aczone (dapsone) Gel for acne treatment by Allergan and the Xeljanz (tofacitinib citrate) for rheumatoid arthritis by Pfizer Labs.

An abstract of the article "Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trial," by A. Vaclavkova and colleagues is presented.

The article presents information on a report which reveals that resveratrol, a natural product present in red wine, activates a pathway linked to antiaging effects. It informs that researchers are trying to develop a maligned approach for finding resveratrol mimic which activates sirtuin enzymes and helps in regulating a host of aging-associated gene. The clinical trials on resveratrol reveal that it helps in the treatment of diseases like Type 2 diabetes and psoriasis.

The article discusses research in the article "Efficacy of Apremilast in the Treatment of Moderate to Severe Psoriasis: A Randomised Controlled Trial" by K. Papp et al. which found that the drug apremilast is effective for the long term treatment of psoriasis.

A learning zone article helped Dan Taylor to understand the condition's physical and psychological effects. [ABSTRACT FROM AUTHOR]

The article offers information on Stelara, a psoriasis treatment, manufactured by Centocor Ortho Biotech Inc. It mentions that Stelara was recently approved by the Food and Drug Administration (FDA) and notes its usefulness to patients with psoriasis who are subject for phototherapy. It highlights the pharmacological details and the clinical trials of ustekinumab. Moreover, the dosage of the said medication is also given.

The article, part of a special advertising section, focuses on advertising for a drug to treat psoriasis created by the advertising agency DraftFCB. The advertising was presented with a CLIO Award in its first annual competition in the health care category. The drug, a biologic, was created and produced by the company Centocor Ortho Biotech.

The article reports on the approval issued by the U.S. Food and Drug Administration (FDA) for the marketing of Fougera's generic Calcipotriene Topical Solution 0.005% (scalp solution). The solution is indicated for the treatment of chronic, moderately severe psoriasis of the scalp. It is applied only to lesions and should be avoided on the forehead.

Focuses on the biological therapy for chronic skin condition psoriasis. Factors that triggered the onset of the disease; Development of two biological therapies made of proteins for the treatment of moderate to severe plaque psoriasis in adult; Explanation of how the body's own defenses can be used for the treatment of psoriasis. INSET: Facts about psoriasis.

Reports that Novo Nordisk has licensed North American rights to ZymoGenetics' patents covering interleukin-20, a member of the cytokine family that is being developed as a psoriasis treatment.